Clinical trial
A Non-interventional Study of Nab-paclitaxel (Abraxane®) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)
NCT02799862 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional Study of Nab-paclitaxel (Abraxane®) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)
- Lead sponsor
- iOMEDICO AG
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 29, 2016
- Completion date
- June 6, 2021
- Enrollment
- 408 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.